USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
A new wave of gene therapies is set to revolutionize treatments over the next decade for inherited diseases which are either untreatable or which do not have a satisfactory treatment outcome at present
28-Sep-2018
North America
Technology Research
D85E-01-00-00-00
HC03086-NA-TR_22368
The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme replacement therapies, usually prescribed for inherited diseases, to correct the root cause of the disorders. In other words, they are not corrective therapies. Gene therapy offers exactly what small molecule drugs and enzyme therapy therapies don't- they can offer corrective solutions for inherited disorders.
A new wave of gene therapy breakthroughs can be expected to follow in the next few years after a two-decade long hiatus that witnessed very few proven gene therapy drug candidates. This potential in-flux of gene therapy candidates is due to the two fundamental factors. First, the refining and development of cutting-edge vector platform both by academia and by pharmaceutical industry. This has resulted in the widely used advanced Adeno-associated viral vectors and Lentiviral vectors, both of which are used according to the applicability. Second, the development of novel gene editing tools such as TALENs, Meganucleases, CRISPR/Cas along with the improvement of old techniques such as ZFNs have helped improve the translational capability of gene therapies currently in clinical development.
In the following study, the development of gene editing tools as well as gene-transfer enabling vectors is traced over the last decade or so while also putting into perspective the number of gene therapy candidates currently in clinical development in addition to the various potential cures and satisfactory treatments that await patients affected by genetic diseases .
1.1 Research Scope – Application of Technology
1.2 Research Methodology – The Frost & Sullivan Core Value
1.3 Key Findings
2.1 Currently Available Gene Therapy Treatments on the Market
3.1 An Introduction to Gene Editing Tools
3.2 Clustered Regularly Interspaced Short Palindromic Repeats
3.2.1 CRISPR Patent Battle- Event Timeline
3.3 Zinc Finger Nucleases (ZFNs)
3.4 Transcription Activator-like Effector Nucleases
3.5 ARC- Nucleases (ARCUS)
4.1 Building a Gene Therapy Platform- Technology Segmentation
4.2 Methods of Gene Therapy and types of vectors used
4.3 A Timeline Highlighting Gene Therapy Breakthroughs
4.4 More Recent Successes in Gene Therapy Development
4.5 A Brief Account of Setbacks Encountered in Gene Therapy Development Over the Years
4.6 Viral Vectors- Overview
5.1 Key Factors Aiding Development of Gene Therapy Breakthroughs
5.2 Key Factors Restricting the Growth of Gene Therapy Technology
6.1 A Comprehensive List of Gene Therapy Companies (US & EU)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
6.1 A Comprehensive List of Gene Therapy Companies (US & EU) (continued)
7.1 Gene Therapy Leads in Pre-clinical Development
7.2 Gene Therapies in Phase 1 Clinical Study
7.3 Gene Therapies in Phase 2 Clinical Study
7.4 Gene Therapies in Phase 3 Clinical Development
7.5 Gene Therapies Segmentation Based on Development phase
8.1. Patent Research Scope and Concepts
8.2 Top 20 Patent Holders in the Pharmaceutical Industry
8.3 Global Office-wise Patent Distribution Trend- Top 3 countries
8.4 Patent Trends of Gene Editing Tools, 2015-2017
8.5 Year-wise Patent Publication Related to Gene Therapy, 2010–2018
9.1 Growth Opportunity 1: CNS and Heart Diseases
9.2 Growth Opportunity 2: One-time Treatment Design
9.3 Growth Opportunity 3: Better Pricing Model
10.1 Key Contacts
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Deepak Jayakumar |
| Industries | Healthcare |
| WIP Number | D85E-01-00-00-00 |
| Is Prebook | No |
Gene Editing and Gene Therapy Breakthroughs to Propel Mainstream Disease Treatments
$4,950.00
Special Price $3,712.50 save 25 %